article thumbnail

New FDA head needs to examine the accelerated approval program

World of DTC Marketing

The analysis focused on Medicare Part B and Part D spending — which covers outpatient medical care and prescription drugs, respectively, — in 2017, 2018 and 2019, the researchers said. Between 2011 and 2018, cumulative spending on 44 FDA-approved oral targeted therapy drugs was $3.5

FDA 234
article thumbnail

The rise of prescription drug abuse and drug diversion

pharmaphorum

As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Drug diversion is the channelling of prescription drugs from a medical source into the illegal market. The post The rise of prescription drug abuse and drug diversion appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Corporations: “get healthcare costs under control”

World of DTC Marketing

On a percentage basis, the figure for 2020 was Independence’s highest profit margin since 2011, records show. It’s going to affect every sector of healthcare, from prescription drugs to hospitals, and is going to squeeze profit margins. The company also did well in the stock market. How does pharma respond?

article thumbnail

“Game-changing” obesity drug over-promising?

World of DTC Marketing

Novo Nordisk has admitted that it would not be able to keep up, adding that it would likely take until early 2022 for the supply to stabilize and that some patients “are experiencing an approximate one month or longer delay in filling prescriptions for Wegovy.”

Insurance 271
article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend. As the U.S.

article thumbnail

FDA extends review of GSK’s myelofibrosis drug

Pharmaceutical Technology

The FDA will make an approval decision by the new Prescription Drug User Fee Act (PDUFA) target action date of 16 September 2023. Novartis and Incyte Corp’s Jakafi was the first FDA-approved drug for the treatment of myelofibrosis in November 2011. The reason for this review extension was undisclosed in the announcement.

article thumbnail

Thursday pharma headlines

World of DTC Marketing

regulators knew about reports of suicidal behavior in men taking the anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label. prescriptions of finasteride, as the drug is known, for hair loss increased to over 2.4 Annual U.S.

Pharma 180